Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Liberman

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 2, 2011
Concerns regarding sacral neuromodulation as a treatment option for medical-refractory overactive bladderDaniel Liberman, Luc Valiquette
Current Opinion in Supportive and Palliative Care|May 31, 2012
Renal and urologic problems: management of ureteric obstructionDaniel Liberman, Michael McCormack
Urology Practice|June 14, 2023
Editorial CommentaryDaniel Liberman, Luc Valiquette
The Canadian Journal of Urology|October 25, 2011
GreenLight 180W XPS photovaporization of the prostate: how I do itKevin C Zorn, Daniel Liberman
Translational Andrology and Urology|January 28, 2016
Urinary adverse effects of pelvic radiotherapyDaniel Liberman, Brian Mehus, Sean P Elliott
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 14, 2019
Iatrogenic ureteral injury after gynecological surgeryAriane P Smith, Amelie Bazinet, Daniel Liberman
Urology|June 15, 2016
Sacral Neuromodulation in Urological PracticeDaniel Liberman, Michael J Ehlert, Steven W Siegel
The Canadian Journal of Urology|February 12, 2022
Biochemical failure-rate and preservation of erectile function after prostate seed brachytherapy in early-onset prostate cancerCédric Charrois-Durand, Daniel Taussky, Guila Delouya, et al.
Brachytherapy|July 25, 2022
Subclinical inflammation as a predictor for erectile dysfunction after brachytherapy for localized prostate cancerLaurianne Rita Garabed, Daniel Taussky, Guila Delouya, et al.
Female Pelvic Medicine & Reconstructive Surgery|September 28, 2017
Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive BladderDaniel Liberman, Olufenwa Milhouse, Marta Johnson-Mitchell, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 2, 2011
Concerns regarding sacral neuromodulation as a treatment option for medical-refractory overactive bladderDaniel Liberman, Luc Valiquette
Current Opinion in Supportive and Palliative Care|May 31, 2012
Renal and urologic problems: management of ureteric obstructionDaniel Liberman, Michael McCormack
Urology Practice|June 14, 2023
Editorial CommentaryDaniel Liberman, Luc Valiquette
The Canadian Journal of Urology|October 25, 2011
GreenLight 180W XPS photovaporization of the prostate: how I do itKevin C Zorn, Daniel Liberman
Translational Andrology and Urology|January 28, 2016
Urinary adverse effects of pelvic radiotherapyDaniel Liberman, Brian Mehus, Sean P Elliott
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 14, 2019
Iatrogenic ureteral injury after gynecological surgeryAriane P Smith, Amelie Bazinet, Daniel Liberman
Urology|June 15, 2016
Sacral Neuromodulation in Urological PracticeDaniel Liberman, Michael J Ehlert, Steven W Siegel
The Canadian Journal of Urology|February 12, 2022
Biochemical failure-rate and preservation of erectile function after prostate seed brachytherapy in early-onset prostate cancerCédric Charrois-Durand, Daniel Taussky, Guila Delouya, et al.
Brachytherapy|July 25, 2022
Subclinical inflammation as a predictor for erectile dysfunction after brachytherapy for localized prostate cancerLaurianne Rita Garabed, Daniel Taussky, Guila Delouya, et al.
Female Pelvic Medicine & Reconstructive Surgery|September 28, 2017
Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive BladderDaniel Liberman, Olufenwa Milhouse, Marta Johnson-Mitchell, et al.
Pageof 5